Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 3, 2013, Pages 447-455

  Spitaleri, G ^a   Berardi, R ^b   Pierantoni, C ^b   De Pas, T ^a   Noberasco, C ^a   Libbra, C ^c   Gonzalez Iglesias R ^c   Giovannoni, L ^c   Tasciotti, A ^c   Neri, D ^d   Menssen, H D ^c   De Braud, F ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Azienda Ospedaliera Umberto I   (Italy)

^c Philogen SpA   (Italy)

^d ETH ZURICH   (Switzerland)

Author keywords

Armed antibody; Immunocytokine; L19 TNF; Phase I II trial; Vascular targeting; Vasodisruptive therapy

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY L19 TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; L19MTNFALPHA PROTEIN; MONOCLONAL ANTIBODY;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANEMIA; ANTIBODY PRODUCTION; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; BONE METASTASIS; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTOSIS; LOW BACK PAIN; LYMPHOCYTE SUBPOPULATION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PAROTID ADENOID CYSTIC CARCINOMA; PAROTID GLAND CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; THYMOMA; VATER PAPILLA CARCINOMA; CHEMISTRY; COHORT ANALYSIS; DISEASE COURSE; DOSE RESPONSE; METHODOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CYTOKINES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

MLCS; MLOWN;

EID: 84876331190     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1327-7     Document Type: Article

References (36)

1. Balza E, Mortara L, Sassi F et al (2006) Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 12:2575-2582
2. Bartsch HH, Nagel GA, Mull R et al (1988) Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies. Mol Biother 1:21-29
3. Bartsch HH, Pfizenmaier K, Schröder M, Nagel GA (1989) Systemic versus local therapy with recombinant tumor necrosis factor-alpha (r-TNF-alpha) in patients with advanced tumors. Onkologie 12:136-141
4. Blick M, Sherwin SA, Rosenblum MG, Guttermann J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989
5. Borsi L, Balza E, Carnemolla B et al (2003) Selective targeted delivery of TNF-alpha to tumor blood vessels. Blood 102:4384-4392
6. Brett J, Gerlach H, Nawroth P et al (1989) Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 169:1977-1991
7. Carswell EA, Old LJ, Kassel RL et al (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670
8. Chapman PB, Lester TJ, Casper ES et al (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5:1942-1951
9. Creaven PJ, Brenner DE, Cowens JW et al (1989) A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 23:186-191
10. Curnis F, Sacchi A, Corti A (2002) Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 110:475-482
11. de Wilt JH, ten Hagen TL, van Tiel ST et al (2000) Tumor necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82:1000-1003
12. 131I-L19SIP (radretumab) in solid tumors: results of a phase I trial. Eur J Nucl Med (submitted)
13. Erba PA, Sollini M, Orciuolo E et al (2012) Radioimmunotherapy with radretumab (131I-L19SIP) in patients with relapsed Hodgkin lymphoma and other lymphoproliferative malignancies. J Nucl Med 53:922-927
14. Folli S, Pelegrin A, Chalandon Y et al (1993) Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 53:829-836
15. Gamm H, Lindemann A, Mertelsmann R, Herrmann F (1991) Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 27:856-863
16. Gregorc V, Santoro A, Bennicelli E et al (2009) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 101:219-224
17. Gregorc V, Citterio G, Vitali G et al (2010) Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer 46:198-206
18. Halin C, Gafner V, Villani ME et al (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 63:3202-3210
19. Hersh EM, Metch BS, Muggia FM et al (1991) Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother 10:426-430
20. Hoving S, Seynhaeve ALB, van Tiel ST et al (2006a) Addition of low-dose tumor necrosis factor-a to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats. Anticancer Drugs 16:667-674
21. Hoving S, Seynhaeve AL, van Tiel ST et al (2006b) Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 17:949-959
22. Kestell P, Zhao L, Jameson MB et al (2001) Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 314:159-166
23. Lejeune FJ, Lienard D, Matter M, Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:1-17
24. Lienard D, Ewalenko P, Delmotte JJ et al (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60
25. Mavligit GM, Zukiwski AA, Charnsangavej C et al (1992) Regional biologic therapy. Heptic arterial infusion of recombinant humor tumor necrosis factor in patients with liver metastases. Cancer 69:557-561
26. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5:436-446
27. Papadia F, Basso V, Patuzzo R et al (2012) Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol. doi: 10.1002/jso.23168
28. Pini A, Viti F, Santucci A et al (1998) Design and use of a phage display library. J Biol Chem 273:21769-21776
29. Räth U, Kaufmann M, Schmid H et al (1991) Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascitis. Eur J Cancer 27:121-125
30. Sacchi A, Gasparri A, Gallo-Stampino C et al (2006) Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 12:175-182
31. Santimaria M, Moscatelli G, Viale GL et al (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9:571-579
32. Sauer S, Erba PA, Petrini M et al (2009) Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113:2265-2274
33. Schwartz JE, Scuderi P, Wiggins C et al (1989) A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1:207-214
34. Spriggs DR, Sherman ML, Michie M et al (1988) Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80:1039-1044
35. Talmadge JE, Tribble HR, Pennington RW et al (1987) Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47:2563-2570
36. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216